LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Начало・Списък с акции・Novartis AG

Novartis AG

Затворен

148.98 0.35

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

148.11

Максимум

149.04

Ключови измерители
By Trading Economics
Приходи	747M 3.2B
Продажби	189M 14B
P/E Средно за сектора	20.871 49.888
EPS	1.65
Дивидентна доходност	3.25
Марж на печалбата	23.336
Служители	75,267
EBITDA	338M 5.4B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+7.3% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	3.25% 2.38%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-351M 278B
Предишно отваряне	148.63
Предишно затваряне	148.98

Novartis AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.04.2026 г., 09:05 ч. UTC

Печалби

Novartis Earnings Hit by Generic Competition -- Update

28.04.2026 г., 05:51 ч. UTC

Печалби

Novartis Could Upgrade Future Growth Outlook

27.03.2026 г., 10:24 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27.03.2026 г., 06:36 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Biotech Excellergy for Up to $2 Billion

28.04.2026 г., 09:18 ч. UTC

Пазарно говорене

Печалби

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

28.04.2026 г., 07:26 ч. UTC

Пазарно говорене

Печалби

Novartis's Results Are Mixed -- Market Talk

28.04.2026 г., 05:07 ч. UTC

Печалби

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

28.04.2026 г., 05:05 ч. UTC

Печалби

Novartis: On Track to Deliver Full-Year Guiance

28.04.2026 г., 05:04 ч. UTC

Печалби

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

28.04.2026 г., 05:04 ч. UTC

Печалби

Novartis Sees 2026 Net Sales Growing by Low Single-digit

28.04.2026 г., 05:03 ч. UTC

Печалби

Novartis 1Q Core EPS $1.99

28.04.2026 г., 05:03 ч. UTC

Печалби

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

28.04.2026 г., 05:02 ч. UTC

Печалби

Novartis 1Q Core Operating Profit $4.90B

28.04.2026 г., 05:02 ч. UTC

Печалби

Analysts Saw Novartis 1Q Sales at $13.34B

28.04.2026 г., 05:01 ч. UTC

Печалби

Novartis 1Q Sales $13.11B

28.04.2026 г., 05:00 ч. UTC

Печалби

Novartis Backs 2026 View

28.04.2026 г., 05:00 ч. UTC

Печалби

Novartis AG 1Q EPS $1.65

28.04.2026 г., 05:00 ч. UTC

Печалби

Novartis AG 1Q Net Pft $3.2B

28.04.2026 г., 05:00 ч. UTC

Печалби

Novartis AG 1Q Adj EPS $1.99

24.04.2026 г., 05:20 ч. UTC

Печалби

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24.04.2026 г., 05:19 ч. UTC

Печалби

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24.04.2026 г., 05:19 ч. UTC

Печалби

Novartis: Prequalification Is a Process Run by the WHO

10.04.2026 г., 11:45 ч. UTC

Пазарно говорене

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Novartis Likely to Confirm Guidance -- Market Talk

30.03.2026 г., 09:37 ч. UTC

Пазарно говорене

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27.03.2026 г., 07:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27.03.2026 г., 06:22 ч. UTC

Придобивния, сливания и поглъщания

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27.03.2026 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27.03.2026 г., 06:04 ч. UTC

Придобивния, сливания и поглъщания

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27.03.2026 г., 06:03 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Сравнение с други в отрасъла

Ценова промяна

Novartis AG Прогноза

Ценова цел

By TipRanks

7.3% нагоре

12-месечна прогноза

Среден 159.23 USD 7.3%

Висок 177.055 USD

Нисък 141 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Novartis AG през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Novartis AG през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.